The Phase 3 study evaluating crovalimab in adult and adolescent participants with atypical hemolytic uremic syndrome (aHUS) reached its primary completion on October 9, 2025. This milestone for the study (NCT04861259) indicates that all participants have completed the primary endpoint assessment, marking a significant step towards potential data analysis and reporting.

Background

Atypical Hemolytic Uremic Syndrome (aHUS) is a rare, life-threatening genetic disease characterized by chronic, uncontrolled activation of the complement system, leading to inflammation and damage to small blood vessels throughout the body. This can result in severe organ damage, particularly to the kidneys. Crovalimab is an investigational drug being evaluated as a potential treatment for this condition.

Trial design

The study, officially titled "A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)" (NCT04861259), is a Phase 3 trial. It aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants diagnosed with atypical hemolytic uremic syndrome. The trial enrolled a total of 83 participants and is currently in an "ACTIVE_NOT_RECRUITING" status.

What this means

The primary completion of the Phase 3 study for crovalimab in aHUS signifies that the main data collection period for the trial's primary outcome measures has concluded. This is a critical step in the drug development process, as it precedes the comprehensive analysis of the collected data on efficacy, safety, pharmacokinetics, and pharmacodynamics. The results from this analysis will be crucial for understanding the potential role of crovalimab in treating aHUS.

Source

The information regarding the primary completion of this clinical trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04861259, titled "A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)," was posted on 2025-10-09 on clinicaltrials.gov.